Clinical Value Of CfDNA Content In Peripheral Blood Of Patients With Triple Negative Breast Cancer

Objective:To compare the cfDNA levels in the plasma of triple-negative breast cancer patients,non-triple-negative breast cancer patients,breast fibroadenoma patients and healthy individuals,as well as the cfDNA levels in the plasma of triple negative breast cancer patients in terms of tumor diameter,clinical stage,lymph node metastasis status,and to investigate the clinical value of cfDNA content in peripheral blood in the diagnosis and prognosis evaluation of breast cancer patients,especially triple negative breast cancer patients.Methods:The patients who were admitted to the First Central Hospital of Baoding from October 2019 to December 2020 due to breast tumors were selected as the research object,and the patients’ clinical data were fully characterized,including thirty-eight breast cancer patients with triple-negative classification confirmed by pathology and immunohistochemistry,fifty non-triple-negative breast cancer patients and fifty breast fibroadenoma patients were selected by random number method.Fifty healthy women in Baoding First Central Hospital during the same period were randomly divided into four groups:triple negative breast cancer group,non-triple negative breast cancer group,breast fibronenoma group and healthy population control group.Peripheral blood was collected from breast cancer patients,breast fibroadenoma patients,and healthy individuals,and plasma was collected by centrifugation,and the cfdna concentration in plasma was measured by a fully automated medical PCR(polymerase chain reaction,PCR)analysis system.Differences in plasma cfdna concentration in each group were compared and compared to changes in plasma cfdna concentration in patients with triple-negative breast cancer in terms of tumor size,different clinical stages,and presence or absence of metastasis in lymph nodes.All study materials were approved by the medical ethics committee of the first Central Hospital of Baoding,and informed consent was obtained from the enrolled individuals.SPSS 25.0 was used for analysis,the data that conformed to the normal distribution measurement were expressed as mean ± standard deviation,the SNK-q test was used among the mean of multiple samples,the t test was used for the two independent samples with normal distribution and homogeneous variance,otherwise the nonparametric rank sum test was used,all with p< 0.05 as significant difference.Results:1.Results of cfDNA concentration determination in peripheral blood of patients in each group.The cfDNA concentration in the peripheral blood of 38 patients with triple-negative breast cancer group was 23.64±5.00ng/ml,50 patients with non-triple-negative breast cancer group was 13.25 ± 3.86ng/ml,50 patients with breast fibronenoma group was 3.61±1.52ng/ml,and 50 healthy people control group was 3.34±1.59ng/ml.Compared with the fibroadenoma group and the healthy group,the peripheral blood cfDNA concentration of breast cancer patients was significantly higher(p<0.001),and the cfDNA concentration in peripheral blood of triple negative breast cancer group was significantly higher than that of non-triple negative breast cancer group(p<0.001),and there was no significant difference in cfDNA concentration in peripheral blood between fibroadenoma group and healthy group(p>0.05).2.Relationship between cfDNA concentration in peripheral blood of patients and clinicopathological indicators of triple-negative breast cancer.The concentration of cfDNA in peripheral blood of patients with stage III-IV triple-negative breast cancer was significantly higher than that of patients with stage I-II(28.98 ± 2.99ng/ml vs 20.87 ± 3.25ng/ml,t=7.50, p<0.001),cfDNA concentration in peripheral blood was also significantly higher in the triple negative breast cancer group with lymph node metastasis than in the group without lymph node metastasis(27.72±3.29ng/ml vs 20.00±3.02ng/ml,t=7.56,p<0.001).The cfDNA concentration in peripheral blood of triple-negative breast cancer patients with tumor volume less than or equal to 2cm and those with tumor volume greater than 2cm were 23.17±4.71ng/ml vs 23.76±5.19ng/ml,t=1.07,p>0.05.There was no significant correlation between cfDNA concentration in peripheral blood and tumor size in triple-negative breast cancer group.Conclusion:1.The results of this experiment showed that the plasma cfDNA concentration level of patients with triple-negative breast cancer group and non-triple-negative breast cancer group was significantly higher than that of the breast fibroadenoma group and healthy population control group.These results suggest that the cfDNA concentration in plasma is of some reference value for the diagnosis of breast cancer and may serve as a new biomarker for the early diagnosis of breast cancer.2.Plasma cfDNA concentration in patients with triple-negative breast cancer was significantly higher than that in patients with non-triple-negative breast cancer,suggesting that this index may be of significance for different molecular classification of breast cancer.3.The cfDNA concentration in the peripheral blood of patients with triple-negative breast cancer group was significantly higher than that of the non-triple-negative breast cancer group.The higher the cfDNA concentration in the peripheral blood of patients with triple-negative breast cancer with late clinical stage and lymph node metastasis,the higher the cfDNA concentration in the peripheral blood may indicate the higher invasion and poor prognosis of breast cancer.